The Neuro-Oncology Program is one of the most well-known and oldest cancer programs at Duke, having celebrated its 75th anniversary in 2012. The first to establish brain tumor research and clinical activities at Duke was Dr. Barnes Woodhall, who came to Duke from Johns Hopkins in 1937. As the second Chancellor for Health Affairs, Dr. W oodhall strongly supported brain tumor research and clinical activities, which has continued to this day with the recent designation of Neuro-Oncology as a Program of Distinction by Chancellor Victor Dzau, M.D. The program includes two leaders as well as 28 primary and 3 secondary members, a diverse group of basic, translational and clinical scientists and physician-scientists who represent 12 departments within the School of Medicine. The program funding portfolio includes two large infrastructure grants with Dr. Darell Bigner as principal investigator: an NCI Clinical Program Project Grant (P01); and the only fully funded Pediatric Brain Tumor Foundation Institute Grant, now in its 10th year. Program members hold a total of 11NCI-funded grants for a total of more than $3.8M in annual direct cost. Additional annual direct cost funding includes $1.7M in other NIH-funded awards, $1.3M in other peer-reviewed awards, $5M in foundation award and $3.4M non-peer-reviewed funding, for a total of more than $15.3M in annual research funding. Primary program members published more than 443 manuscripts during the funding period, 98% of which were intra-programmatic collaborations, 25% of which were inter-programmatic, and 33% were intra- programmatic and with external investigators. Research ranges from the most basic types of genomic research to epidemiology and causation efforts. As described within the Specific Aims of the Program, the following areas are the highlighted areas of research: basic genomics research; establishment of xenografts of all types of adult and pediatric brain tumors and using them to screen drugs and other agents; development of transgenic models of brain stem and other gliomas to identify driver oncogenes; development of oncolytic virotherapy of primary and metastatic CNS tumors with genetically recombinant poliovirus; development of peptide dendritic cell and other types of cell, and antibody-based immunotherapy; development of monoclonal antibodies, single fragment chain antibodies, and immunoconjugates with bacterial toxins and radioactivity; design and execution of Phase I, II, and III clinical trials; and molecular epidemiology studies to identify causation factors of malignant brain tumors. A final goal of the Neuro-Oncology Program is the maintenance of a brain tumor tissue bank, now in its 30th year of operation. The three technicians and neuro-pathologist overseeing this bank are available 24 hours a day, 7 days a week to collect adult and pediatric brain tumor tissue, as well as blood and serum matched with the cases.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014236-44
Application #
9404314
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2018-01-01
Budget End
2018-12-31
Support Year
44
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Duke University
Department
Type
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Wu, Mengxi; Huang, Po-Hsun; Zhang, Rui et al. (2018) Circulating Tumor Cell Phenotyping via High-Throughput Acoustic Separation. Small 14:e1801131
Vlahovic, Gordana; Meadows, Kellen L; Hatch, Ace J et al. (2018) A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer. Oncologist 23:782-790
Xu, Yinghui; Liu, Hongliang; Liu, Shun et al. (2018) Genetic variant of IRAK2 in the toll-like receptor signaling pathway and survival of non-small cell lung cancer. Int J Cancer 143:2400-2408
Feng, Yun; Wang, Yanru; Liu, Hongliang et al. (2018) Novel genetic variants in the P38MAPK pathway gene ZAK and susceptibility to lung cancer. Mol Carcinog 57:216-224
Naqvi, Ibtehaj; Gunaratne, Ruwan; McDade, Jessica E et al. (2018) Polymer-Mediated Inhibition of Pro-invasive Nucleic Acid DAMPs and Microvesicles Limits Pancreatic Cancer Metastasis. Mol Ther 26:1020-1031
Wen, Juyi; Liu, Hongliang; Wang, Lili et al. (2018) Potentially Functional Variants of ATG16L2 Predict Radiation Pneumonitis and Outcomes in Patients with Non-Small Cell Lung Cancer after Definitive Radiotherapy. J Thorac Oncol 13:660-675
Li, Bo; Wang, Yanru; Xu, Yinghui et al. (2018) Genetic variants in RORA and DNMT1 associated with cutaneous melanoma survival. Int J Cancer 142:2303-2312
Gearhart-Serna, Larisa M; Jayasundara, Nishad; Tacam Jr, Moises et al. (2018) Assessing Cancer Risk Associated with Aquatic Polycyclic Aromatic Hydrocarbon Pollution Reveals Dietary Routes of Exposure and Vulnerable Populations. J Environ Public Health 2018:5610462
Bakthavatsalam, Subha; Sleeper, Mark L; Dharani, Azim et al. (2018) Leveraging ?-Glutamyl Transferase To Direct Cytotoxicity of Copper Dithiocarbamates against Prostate Cancer Cells. Angew Chem Int Ed Engl 57:12780-12784
Dai, Ziwei; Mentch, Samantha J; Gao, Xia et al. (2018) Methionine metabolism influences genomic architecture and gene expression through H3K4me3 peak width. Nat Commun 9:1955

Showing the most recent 10 out of 513 publications